Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.56B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 1.86M
Average 3.08M
SRPT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sarepta Therapeutics, Inc.NASDAQ: SRPT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $153.96M fell 80.1% year over year, behind the -34.5% change in trailing-twelve-month research & development. Sequentially, it fell 52.7% from the prior quarter. Over 3 fiscal years it compounded at +20.2% a year.
Context
- Research & development amounted to 69.2% of revenue in FY2025, up 26.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -80.1% toward the trailing-twelve-month pace of -34.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.52B USD
- Year-over-year change
- +89.2%
- 4-year CAGR
- +18.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.52B | +89.2% |
| FY2024 | 2024-12-31 | 804.52M | -8.3% |
| FY2023 | 2023-12-31 | 877.39M | +0.0% |
| FY2022 | 2022-12-31 | 877.09M | +13.7% |
| FY2021 | 2021-12-31 | 771.18M | — |
Research & Development vs competitors
How SRPT compares with its peers on the latest reported figures
- SRPT's LTM Mar 2026 research & development of $902.58M is the 3rd highest of the 11 companies compared; the peer median is $275.38M.
- Its year-over-year change of -34.5% is the lowest of 11, against a peer median of +15.2%.
- Research & development amounts to 41.3% of revenue for SRPT, versus a peer median of 96.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.51B | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Jun 2026 | $445.71M | +17.2% | +40.8% | — | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Mar 2026 | $189.6M | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $92.92M | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $58.35M | -32.7% | +9.5% | — | |
| LTM Mar 2026 | $58.13M | +16.8% | +6.7% | — | |
| Peer median (excluding SRPT) | $275.38M | +15.2% | +12.0% | 96.2% | |
Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 701.89M | 933.01M | 1.24B | 1.9B | 2.2B |
| Cost of Revenue | 97.05M | 139.99M | 150.34M | 319.1M | 881.5M |
| Gross Profit | 604.84M | 793.02M | 1.09B | 1.58B | 1.32B |
| Gross Margin | 86.2% | 85.0% | 87.9% | 83.2% | 59.9% |
| Research & Development | 771.18M | 877.09M | 877.39M | 804.52M | 1.52B |
| Selling, General & Admin | 282.66M | 451.42M | 481.87M | 557.87M | 478.94M |
| Operating Expenses | 1.06B | 1.33B | 1.36B | 1.36B | 1.97B |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| EBITDA | (317.41M) | (594.85M) | (453.69M) | 316.89M | (647.97M) |
| EBITDA Margin | -45.2% | -63.8% | -36.5% | 16.7% | -29.5% |
| Operating Income | (459.71M) | (536.2M) | (267.82M) | 218.08M | (657.77M) |
| Operating Margin | -65.5% | -57.5% | -21.5% | 11.5% | -29.9% |
| Interest Income | 511K | 27.72M | 85.97M | 71.77M | 19.57M |
| Interest Expense | 63.53M | 53.25M | 22.01M | 18.39M | 9.73M |
| Other Income / Expenses | 40.76M | (153.76M) | (252.27M) | 42.69M | (44.45M) |
| Income Before Tax | (418.95M) | (689.96M) | (520.1M) | 260.77M | (702.23M) |
| Pre-Tax Margin | -59.7% | -73.9% | -41.8% | 13.7% | -31.9% |
| Income Tax Expense | (168K) | 13.53M | 15.88M | 25.54M | 11.19M |
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Net Margin | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
| EPS (Basic) | (5.15) | (8.03) | (5.80) | 2.47 | (7.13) |
| EPS (Diluted) | (5.15) | (8.03) | (5.80) | 2.34 | (7.13) |
| Weighted Avg Shares | 81.26M | 87.56M | 92.4M | 95.08M | 104.79M |
| Weighted Avg Shares (Diluted) | 81.26M | 87.56M | 92.4M | 107.88M | 104.79M |
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
Intrinsic Alpha fair value
Locked
Current Price
$14.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.